Sandoz launches first generic version of Prograf® capsules
- Details
- Category: Novartis
Sandoz has announced the introduction of tacrolimus capsules, a generic equivalent of Prograf®, in the US. Tacrolimus is an immunosuppressive treatment used to help prevent rejection of a kidney or liver transplant.
Abbott Partners With Beech-Nut to Provide New Parents with Nutrition Education and Support
- Details
- Category: Abbott
Abbott (NYSE: ABT), the maker of Similac® Infant Formulas, has partnered with baby food maker Beech-Nut Nutrition to provide new parents with infant and toddler parenting tips, tools and offers through the companies Web sites.
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD
- Details
- Category: Nycomed
Nycomed and Forest Laboratories, Inc. (NYSE: FRX) announced that they have
entered into an exclusive development, manufacturing and commercialisation
agreement in the United States for Daxas® (roflumilast), a once-daily oral treatment
for patients suffering from symptomatic Chronic Obstructive Pulmonary Disease
(COPD).
Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim has announced at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 (planned brand name Tovok™) is the first orally-administered, irreversible dual inhibitor of EGFR and HER2,(1) to reach Phase III development in NSCLC.(2)
President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines
- Details
- Category: Pfizer
President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world. For the first time, a second-line regimen of four ARVs will be available for under $500 annually.
Effient(TM) is Now Available in Pharmacies
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and Daiichi Sankyo, Inc. have announced that Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States. The U.S. Food and Drug Administration approved Effient tablets on July 10 for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes (ACS) who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI).
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab)]. This safety review was the subject of an FDA Early Communication in June 2008 pertaining to cases of malignancy in pediatric patients exposed to a TNF
blocker.
More Pharma News ...
- AstraZeneca And Astellas Enter Agreement for Co-Promotion of Symbicort Turbuhaler in Japan
- GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
- Avastin approved in US for the most common type of kidney cancer
- Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva
- FDA Approves ONGLYZA for the Treatment of Type 2 Diabetes in the US
- AstraZeneca PLC Second Quarter & Half Year Results 2009
- Good first six months in 2009 for Boehringer Ingelheim